Add Protein Interaction Network Diagram plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Anti [Amyloid] Therapeutics is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
The development of anti-amyloid therapeutics represents one of the most intensive and consequential endeavors in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- (AD) drug discoveryAβ that is aggregated in amyloid plaques[15]. Unlike lecanemab, donanemab is designed to clear existing amyloid burden rather than prevent new plaque deposition. The FDA approved donanemab on July 2, 2024, marketing it as [Kisunla[/entities/[donanemab[/entities/[donanemab[/entities/[donanemab[/entities/[donanemab--TEMP--/entities)--FIX--.
Clinical Trial Results:
FDA Approval:
Safety:
[Aducanumab[/treatments/[aducanumab[/treatments/[aducanumab[/treatments/[aducanumab[/treatments/[aducanumab--TEMP--/treatments)--FIX-- (marketed as Aduhelm) was the first monoclonal antibody to receive FDA approval for [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, though its approval remained controversial throughout its market life[7]. Developed by Biogen and Neurimmune, aducanumab is a human IgG1 monoclonal antibody that selectively targets aggregated forms of Aβ][7].
Clinical Development:
Controversies:
Safety:
Solanezumab (Eli Lilly): Targeting mid-domain of [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--, solanezumab showed promise in preclinical studies but failed to demonstrate cognitive benefit in Phase 3 trials (EXPEDITION-1, EXPEDITION-2, EXPEDITION3). The antibody primarily bound to soluble monomeric [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- rather than aggregated forms, potentially explaining its limited efficacy.
Bapineuzumab (Eli Lilly/Janssen): This antibody targeted the N-terminus of [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--. Phase 3 trials (BOND, COGNITE) failed to meet primary endpoints in both ApoE4 carriers and non-carriers[9]. ARIA, particularly ARIA-E, was more common in ApoE4 carriers[9].
[Gantenerumab[/treatments/[gantenerumab[/treatments/[gantenerumab[/treatments/[gantenerumab[/treatments/[gantenerumab--TEMP--/treatments)--FIX-- (Roche): Gantenerumab is a fully human IgG1 antibody that binds to aggregated [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX--. The GRADUATE trials (GRADUATE-1 and GRADUATE-2) failed to meet their primary endpoints, showing no significant slowing of cognitive decline despite substantial amyloid reduction. This result raised questions about the timing of anti-amyloid intervention in the disease course.
Verubecestat, developed by Merck, was a potent [BACE1[/entities/[bace1[/entities/[bace1[/entities/[bace1[/entities/[bace1--TEMP--/entities)--FIX-- - [Neuroimaging)[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging[/diagnostics/[neuroimaging--TEMP--/diagnostics)--FIX-- effects: Verubecestat caused hippocampal and whole brain atrophy that appeared by 13 weeks, though it did not progress further
The failure of verubecestat highlighted a critical insight: while reducing tau] were not cleared
Long-term Follow-up:
CAD106, developed by Novartis, represented a second-generation [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- vaccine designed to avoid the T-cell-mediated meningoencephalitis seen with AN-1792[12]. The vaccine uses a viral-like particle (Qβ) displaying Aβ1-6 peptides to stimulate B-cell rather than T-cell responses[12].
Clinical Results:
[Amyloid]-related imaging abnormalities (ARIA) represent the major safety concern associated with anti-amyloid monoclonal antibodies[6][14]. ARIA manifests in two forms:
ARIA-E refers to amyloid-related imaging abnormalities with edema or effusions, appearing as hyperintense signal on FLAIR MRI in the white matter. This is thought to reflect leakage of plasma [proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/[proteins[/proteins and fluid across a compromised [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--[14].
Incidence:
ARIA-H refers to microhemorrhages, cortical [superficial siderosis[/diseases/[superficial-siderosis[/diseases/[superficial-siderosis[/diseases/[superficial-siderosis[/diseases/[superficial-siderosis--TEMP--/diseases)--FIX--, or both, detected via gradient-recalled echo (GRE) or susceptibility-weighted imaging (SWI) MRI sequences[6].
Risk Factors:
Management of ARIA involves:
The anti-amyloid therapeutic landscape has evolved dramatically over the past two decades, from the initial optimism of [the amyloid cascade hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX-- through multiple high-profile failures to the recent approvals of lecanemab and donanemabAbeta plaque reduction following multiple dosing in patients with [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--: a Phase 1b study. J Prev Alzheimers Dis. 2021;8(4):401-408.
The study of Anti Amyloid Therapeutics has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent anti-amyloid trial literature indicates that therapeutic performance depends on intervention timing, molecular species targeted, and integration with biomarker-driven participant selection in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
Add Protein Interaction Network Diagram plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 6 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 35%